Wardell, Suzanne E.
Yllanes, Alexander P.
Chao, Christina A.
Bae, Yeeun
Andreano, Kaitlyn J.
Desautels, Taylor K.
Heetderks, Kendall A.
Blitzer, Jeremy T.
Norris, John D.
McDonnell, Donald P. http://orcid.org/0000-0002-7331-4700
Funding for this research was provided by:
National Institutes of Health (R37DK048807, CA220978)
Potrero Hill Therapeutics
Article History
Received: 13 September 2019
Accepted: 19 September 2019
First Online: 27 September 2019
Change Date: 16 November 2019
Change Type: Correction
Change Date: 16 November 2019
Change Type: Correction
Change Details: The article Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy, written by Suzanne E. Wardell, Alexander P. Yllanes, Christina A. Chao, Yeeun Bae, Kaitlyn J. Andreano, Taylor K. Desautels, Kendall A. Heetderks, Jeremy T. Blitzer, John D. Norris, Donald P. McDonnell, was originally published electronically on the publisher’s internet portal on September 27, 2019 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on November 16, 2019 to © The Author(s) 2019 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The original article has been corrected.
Change Details: The article Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-�� degrader activity in antitumor efficacy, written by Suzanne E. Wardell, Alexander P. Yllanes, Christina A. Chao, Yeeun Bae, Kaitlyn J. Andreano, Taylor K. Desautels, Kendall A. Heetderks, Jeremy T. Blitzer, John D. Norris, Donald P. McDonnell, was originally published electronically on the publisher���s internet portal on September 27, 2019 without open access. With the author(s)��� decision to opt for Open Choice the copyright of the article changed on November 16, 2019 to �� The Author(s) 2019 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The original article has been corrected.
Compliance with ethical standards
:
: Donald McDonnell received research support for this study from Viba Therapeutics and he currently serves as a consultant and as a member of their SAB. Jeremy Blitzer is a founder of Viba Therapeutics. None of the other authors have conflicts to report.
: This article does not contain any studies with human participants performed by any of the authors. All procedures were approved by the Duke University Institutional Animal Care and Use Committee (IACUC) prior to initiating the experiment (protocol A011-16-01 and A272-18-12).